Orthopediatrics Corp (KIDS) · Oct 27, 2026 · Earnings
Beat — Revenue $72.7M vs ~$68.5M consensus; adjusted EPS -$0.23 in line
OrthoPediatrics earnings show a revenue beat and narrower losses, while 2026 guidance remains unchanged and the product launch cycle advances.
OrthoPediatrics is scaling a specialized pediatric-orthopedic implant and bracing platform, with a broad product portfolio and a multi-year launch cycle intended to improve growth and operating leverage. The filing’s real update is that the commercial engine is accelerating while profitability is beginning to improve, though the company is not yet consistently cash-generative.
| Metric | Q3 2025 | Q3 2026 | Change / comparison |
|---|---|---|---|
| Revenue | $61.2M | $72.7M | +19%; above published consensus of ~$68.5M |
| Gross profit | $45.3M | $54.0M | Gross margin held at 74% |
| Operating loss | $(9.4)M | $(4.2)M | Loss narrowed |
| Net loss | $(11.8)M | $(5.9)M | Loss narrowed |
| GAAP diluted EPS | $(0.50) | $(0.25) | Better year over year |
| Adjusted diluted EPS | $(0.24) | $(0.23) | In line with published consensus of ~$0.23 loss |
| Adjusted EBITDA | $6.2M | $6.9M | Improved |
| FY2026 revenue guidance | — | $270M–$273M | Reaffirmed |
| FY2026 adjusted EBITDA | — | ~$25M | Reaffirmed |
| FY2026 free cash flow | — | Breakeven target | Reaffirmed |
Revenue is the clear upside surprise. Third-quarter revenue rose 19% to $72.7 million, ahead of the roughly $68.5 million published consensus, while gross margin stayed at 74%. The result supports the company’s thesis that new products, broader hospital penetration, and higher utilization of deployed instrument sets can drive growth without immediate gross-margin dilution.
The earnings quality improved, but this was not an across-the-board beat. Adjusted EPS was a $0.23 loss, essentially matching the published expectation, while adjusted EBITDA increased to $6.9 million from $6.2 million. GAAP net loss also narrowed to $5.9 million from $11.8 million, helped by lower restructuring and impairment charges. 〔0〕 That makes the quarter modestly better than expected overall, but the positive read is driven mainly by revenue and operating improvement rather than an earnings surprise.
The strategic story is advancing, not changing. Management describes a “multi-year product super cycle” with additional launches planned across trauma, scoliosis, bracing, and enabling technology. 〔1〕 The presentation also points to upcoming launches extending into the first and second halves of 2027, so the business remains in an investment-and-expansion phase rather than a mature profit-maximization phase.
Cash conversion is still the main unfinished piece. The company continues to target free-cash-flow breakeven for full-year 2026, but it held $44.9 million of cash and short-term investments against $98.4 million of debt at September 30, 2026. 〔2〕 Reaffirming breakeven matters because it preserves the existing growth plan, but it does not yet prove that the model can fund its product launches and instrument-set deployments internally.
Bottom line: This is a modestly positive earnings update: revenue beat expectations, margins held, and operating losses narrowed, while adjusted EPS merely met the bar. The broader product-cycle thesis remains intact, but cash breakeven is still a target rather than a completed milestone.
Q4/FY2026 results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!